Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Bank of America

<< Previous

Bullboard Posts

Next >>

Comment by Wino115on Oct 13, 2022 10:17am

112 Views

Post# 35022084

RE:RE:Bank of America

Too funny. I was wondering about that as when I went up to the research site, it listed other analysts and not someone with that name. Good questions though, but a let down from thinking the bank was interested now.

SPCEO1 wrote: I know the BAC "analyst" who asked a question. He is not an analyst but just a shareholder who works at BAC, and apparently the operator was not aware he was not an analyst and let him on the call.

Biobob wrote: That was the best news about this call. They bothered to ask a question... so they are curious about Th1902... maybe smart people like Soleus are starting to smell something. I agree with Wino that we should be optimist in light of what we eard.